Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
CENTOGENE GmbH Rostock
Hereditary angioedema (HAE) is a rare autosomal dominant genetic disorder characterized by recurrent tissue angioedema episodes, mainly caused by mutations in the SERPING1 gene that encodes C1 inhibitor (C1-INH), a protease involved in limiting bradykinin production. Low levels of C1-INH (HAE type 1) or dysfunctional C1-INH (HAE type 2) lead to bradykinin accumulation, resulting in capillary leakage and tissue swelling.
High Molecular Weight Kininogen (HMWK) proteolysis, by active plasma kallikrein, results in bradykinin and cHMWK generation.
The goal of this study is to explore the cHMWK concentrations in HAE type 1/2 patients, as a biomarker for this disease.
The HAEKA study is performed in collaboration with Shire. Shire is a wholly owned subsidiary of Takeda Pharmaceutical Company Limited.
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Informed consent is obtained from the participant
The patient with diagnosis of Hereditary Angioedema (HAE) type 1/2 based on international guidelines
The patient experienced ≥4 HAE attacks within last 12 month before enrolment in the study
The participant is older than 18 years old
You may not be if
Inability to provide informed consent
The patient is not diagnosed with Hereditary Angioedema (HAE) type 1/2
The patient experienced ˂ 4 HAE attacks within last 12 month before enrolment in the study